Vickers Elizabeth R, McClure David L, Naleway Allison L, Jacobsen Steven J, Klein Nicola P, Glanz Jason M, Weintraub Eric S, Belongia Edward A
Marshfield Clinic Research Institute, 1000 North Oak Avenue, Marshfield, WI 54449, United States.
Kaiser Permanente Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227-1098, United States.
Vaccine. 2017 Oct 13;35(43):5872-5877. doi: 10.1016/j.vaccine.2017.08.086. Epub 2017 Sep 6.
Influenza-like illness and inflammation are known risk factors for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). However, few studies have characterized the risk of VTE following influenza vaccination. We examined VTE risk after vaccination in adults 50years old and older within the Vaccine Safety Datalink (VSD).
We used the self-controlled case series method to determine the risk of VTE among age-eligible adults who received influenza vaccine (with or without pandemic H1N1) and experienced a VTE during the months of September through December in 2007 through 2012. Presumptive VTE cases were identified among VSD participants using diagnostic codes, diagnostic tests, and oral anticoagulant prescription. Potential cases were validated by medical record review. The VTE incidence rate ratio was calculated among confirmed cases for the risk window 1 to 10days after vaccination relative to all other person-time from September through December.
Of the 1,488 presumptive cases identified, 508 were reviewed, of which 492 (97%) were confirmed cases of VTE. The analysis included 396 incident, confirmed cases. Overall, there was no increased risk of VTE in the 1 to 10days after influenza vaccination (IRR=0.89, 95% CI 0.69-1.17) compared to the control period. Results were similar when all person-time was censored before vaccination. A post hoc analysis showed an increased risk among current tobacco smokers (IRR=2.57, 95% CI 1.06-6.23). No clustering of VTE was observed in the 1-42days after vaccination.
Overall, there was no evidence that inactivated influenza vaccine was associated with VTE in adults ≥50years old. An increased risk was found among current smokers in a post hoc analysis. These findings are consistent with previous research and support the safety of annual vaccination in this population.
流感样疾病和炎症是已知的静脉血栓栓塞症(VTE)的危险因素,静脉血栓栓塞症包括深静脉血栓形成(DVT)和肺栓塞(PE)。然而,很少有研究描述流感疫苗接种后发生VTE的风险。我们在疫苗安全数据链(VSD)中研究了50岁及以上成年人接种疫苗后的VTE风险。
我们使用自我对照病例系列方法来确定符合年龄条件的接种流感疫苗(有或无大流行H1N1疫苗)并在2007年至2012年9月至12月期间发生VTE的成年人中VTE的风险。使用诊断代码、诊断测试和口服抗凝剂处方在VSD参与者中识别推定的VTE病例。潜在病例通过病历审查进行验证。计算确诊病例中接种疫苗后1至10天风险窗口期相对于9月至12月所有其他观察时间的VTE发病率比。
在识别出的1488例推定病例中,508例接受了审查,其中492例(97%)为确诊的VTE病例。分析包括396例新发确诊病例。总体而言,与对照期相比,流感疫苗接种后1至10天VTE风险没有增加(发病率比=0.89,95%置信区间0.69 - 1.17)。当所有观察时间在接种疫苗前被截尾时,结果相似。事后分析显示当前吸烟者风险增加(发病率比=2.57,95%置信区间1.06 - 6.23)。接种疫苗后1 - 42天未观察到VTE聚集现象。
总体而言,没有证据表明灭活流感疫苗与50岁及以上成年人的VTE有关。事后分析发现当前吸烟者风险增加。这些发现与先前的研究一致,并支持该人群每年接种疫苗的安全性。